---
title: "Right-sizing therapy for HER2-positive breast cancer across early and advanced stages"
id: "nature-reviews-clinical-oncology-1-right-sizing-treatment-for-her2-positive-breast-cancer-evolving-algorithms"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-right-sizing-treatment-for-her2-positive-breast-cancer-evolving-algorithms"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01211-5"
published_at: "2026-10-08T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Right-sizing therapy for HER2-positive breast cancer across early and advanced stages
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-right-sizing-treatment-for-her2-positive-breast-cancer-evolving-algorithms
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01211-5)
- **Published At:** 2026-10-08T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- HER2-positive breast cancer has shifted from a poor-prognosis subtype to a highly treatable disease in both early-stage and metastatic settings owing to multiple targeted agents, including monoclonal antibodies, antibody–drug conjugates and tyrosine-kinase inhibitors. - The antibody–drug conjugate **trastuzumab deruxtecan (T-DXd)** has rapidly moved into earlier lines of therapy, now being used in the first-line metastatic setting, as adjuvant therapy for high-risk residual disease and in neoadjuvant regimens. - This therapeutic expansion creates opportunities to improve outcomes but also generates evidence gaps about optimal **sequencing**, retreatment and which patients require intensified therapy. - For early-stage disease, the concept of “right-sizing” involves: de‑intensification for low‑risk tumours; optimizing neoadjuvant chemotherapy backbones in stage II–III disease; and risk‑based escalation in the post‑neoadjuvant setting for patients with residual disease. - For advanced-stage disease, right‑sizing includes reconsidering maintenance strategies after induction therapy (for example, integration of **trastuzumab–pertuzumab** maintenance), potential use of CDK4/6 inhibitors or tyrosine‑kinase inhibitors as intensification, and how continuous first‑line **T‑DXd–pertuzumab** regimens should be sequenced and how long they should be continued. - Emerging biomarkers—quantitative HER2 expression, intrinsic molecular subtype, imaging response metrics and circulating tumour DNA—are beginning to inform selection and tailoring of therapy across the disease continuum and are approaching clinical implementation. - The central clinical challenge is balancing treatment efficacy, toxicity and patient preference to deliver individualized, evidence‑based escalation or de‑escalation across early and advanced HER2‑positive disease. - The Review highlights conceptual frameworks, response rates with current neoadjuvant regimens, a proposed advanced‑stage treatment algorithm and a biomarker development pathway, while noting that this is a preview of subscription content and that full details are in the full article.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01211-5#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01211-5) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editors ](https://www.nature.com/nrclinonc/editors) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [review articles](https://www.nature.com/nrclinonc/articles?type=review-article) 4. article * Review Article * Published: 08 October 2026 # Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum * [Paolo Tarantino](https://www.nature.com/articles/s41571-026-01211-5#auth-Paolo-Tarantino-Aff1-Aff2) [ORCID: orcid.org/0000-0001-8686-0228](https://orcid.org/0000-0001-8686-0228)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2) [na1](https://www.nature.com/articles/s41571-026-01211-5#na1), * [Carmine Valenza](https://www.nature.com/articles/s41571-026-01211-5#auth-Carmine-Valenza-Aff1-Aff2-Aff3-Aff4)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2),[3](https://www.nature.com/articles/s41571-026-01211-5#Aff3),[4](https://www.nature.com/articles/s41571-026-01211-5#Aff4) [na1](https://www.nature.com/articles/s41571-026-01211-5#na1), * [Elia Segui](https://www.nature.com/articles/s41571-026-01211-5#auth-Elia-Segui-Aff1-Aff2-Aff5)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2),[5](https://www.nature.com/articles/s41571-026-01211-5#Aff5), * [Nancy U. Lin](https://www.nature.com/articles/s41571-026-01211-5#auth-Nancy_U_-Lin-Aff1-Aff2)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2), * [Aleix Prat](https://www.nature.com/articles/s41571-026-01211-5#auth-Aleix-Prat-Aff5-Aff6-Aff7-Aff8) [ORCID: orcid.org/0000-0003-2377-540X](https://orcid.org/0000-0003-2377-540X)[5](https://www.nature.com/articles/s41571-026-01211-5#Aff5),[6](https://www.nature.com/articles/s41571-026-01211-5#Aff6),[7](https://www.nature.com/articles/s41571-026-01211-5#Aff7),[8](https://www.nature.com/articles/s41571-026-01211-5#Aff8), * [Giuseppe Curigliano](https://www.nature.com/articles/s41571-026-01211-5#auth-Giuseppe-Curigliano-Aff3-Aff4) [ORCID: orcid.org/0000-0003-1781-2518](https://orcid.org/0000-0003-1781-2518)[3](https://www.nature.com/articles/s41571-026-01211-5#Aff3),[4](https://www.nature.com/articles/s41571-026-01211-5#Aff4), * [Adrienne G. Waks](https://www.nature.com/articles/s41571-026-01211-5#auth-Adrienne_G_-Waks-Aff1-Aff2)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2) & * … * [Sara M. Tolaney](https://www.nature.com/articles/s41571-026-01211-5#auth-Sara_M_-Tolaney-Aff1-Aff2) [ORCID: orcid.org/0000-0002-5940-8671](https://orcid.org/0000-0002-5940-8671)[1](https://www.nature.com/articles/s41571-026-01211-5#Aff1),[2](https://www.nature.com/articles/s41571-026-01211-5#Aff2) Show authors [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01211-5#citeas) [ Save article ](https://www.nature.com/articles/s41571-026-01211-5/save-research?_csrf=nq4e0DqJq4jiQd6d6pBhySXrNoTglab8) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone one of the most profound therapeutic transformations in oncology. Once associated with poor outcomes, it is now a highly curable disease in the early-stage setting, and a substantial proportion of patients with metastatic disease survive beyond 5 years. This progress reflects the development of multiple HER2-targeted therapies, including monoclonal antibodies, antibody–drug conjugates and tyrosine-kinase inhibitors. Most notably, the HER2-targeted antibody–drug conjugate trastuzumab deruxtecan has rapidly been moved into earlier lines of therapy, with emerging roles in the first-line metastatic setting, adjuvant treatment of high-risk residual disease and neoadjuvant therapy. This expansion creates new opportunities, but also crucial evidence gaps regarding optimal sequencing, retreatment and selection of patients for treatment intensification. As treatment options expand, the central challenge is to right-size therapy across the disease continuum, which is the focus of this Review. In patients with early-stage disease, this right-sizing involves carefully de-intensifying treatment for those with low-risk tumours, optimizing neoadjuvant chemotherapy backbones and escalating therapy for those with residual disease; in patients with advanced-stage disease, it requires optimizing maintenance treatment strategies (for example, using palbociclib or tucatinib) after induction therapy, while integrating these maintenance regimens with the novel option of first-line trastuzumab deruxtecan plus pertuzumab, for which the optimal treatment duration and subsequent sequencing remain uncertain. Tissue, plasma and dynamic imaging-based biomarkers are beginning to inform this process, with several showing promising potential for clinical implementation. ## Key points * HER2-positive breast cancer has been transformed from an aggressive cancer subtype associated with poor patient outcomes into a highly treatable disease across early-stage and advanced-stage settings. * Treatment is moving from a one-size-fits-all approach towards right-sized therapy based on disease burden, biology, response, toxicity and patient preferences. * For early-stage disease, treatment strategies include de-intensification for patients with low-risk tumours, optimized neoadjuvant backbones for patients with stage II–III disease and risk-based post-neoadjuvant escalation for those with residual disease. * The HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) has now been moved into the curative setting, creating new opportunities but also evidence gaps around treatment duration, sequencing and retreatment. * For metastatic disease, first-line and maintenance treatment strategies are becoming more complex, requiring integration of trastuzumab–pertuzumab-based maintenance with emerging intensification approaches using CDK4 and 6 inhibitors or tyrosine-kinase inhibitors, as well as continuous T-DXd–pertuzumab-based first-line treatment. * Biomarkers including quantitative HER2 expression, intrinsic subtype, imaging response and circulating tumour DNA might help to refine treatment selection, and are rapidly approaching prime time. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01211-5) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01211-5) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01211-5) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Conceptual framework for treatment selection in early-stage HER2 + breast cancer across clinical stages.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01211-5/MediaObjects/41571_2026_1211_Fig1_HTML.png) **Fig. 2: Pathological complete response rates with neoadjuvant HER2-targeted regimens.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01211-5/MediaObjects/41571_2026_1211_Fig2_HTML.png) **Fig. 3: Proposed treatment algorithm for advanced-stage HER2-positive (HR +) breast cancer.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01211-5/MediaObjects/41571_2026_1211_Fig3_HTML.png) **Fig. 4: Biomarker journey across the HER2-positive breast cancer disease continuum.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01211-5/MediaObjects/41571_2026_1211_Fig4_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Breast cancer](https://www.nature.com/subjects/breast-cancer) * [Drug development](https://www.nature.com/subjects/drug-development) * [Targeted therapies](https://www.nature.com/subjects/targeted-therapies) * [Tumour biomarkers](https://www.nature.com/subjects/tumour-biomarkers) ## References 1. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. _Science_ **235** , 177–182 (1987). [Article](https://doi.org/10.1126%2Fscience.3798106) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaL2sXhtVSht7s%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3798106) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Human%20breast%20cancer%3A%20correlation%20of%20relapse%20and%20survival%20with%20amplification%20of%20the%20HER-2%2Fneu%20oncogene&journal=Science&doi=10.1126%2Fscience.3798106&volume=235&pages=177-182&publication_year=1987&author=Slamon%2CDJ) 2. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. _N. Engl. J. Med._ **344** , 783–792 (2001). [Article](https://doi.org/10.1056%2FNEJM200103153441101) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3MXisVGktrc%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11248153) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Use%20of%20chemotherapy%20plus%20a%20monoclonal%20antibody%20against%20HER2%20for%20metastatic%20breast%20cancer%20that%20overexpresses%20HER2&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM200103153441101&volume=344&pages=783-792&publication_year=2001&author=Slamon%2CDJ) 3. Tarantino, P. et al. Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies. _CA Cancer J. Clin._ **72** , 165–182 (2022). [Article](https://doi.org/10.3322%2Fcaac.21705) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34767258) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Antibody%E2%80%93drug%20conjugates%3A%20smart%20chemotherapy%20delivery%20across%20tumor%20histologies&journal=CA%20Cancer%20J.%20Clin.&doi=10.3322%2Fcaac.21705&volume=72&pages=165-182&publication_year=2022&author=Tarantino%2CP) 4. Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. _J. Natl Cancer Inst._ (2014). [Article](https://doi.org/10.1093%2Fjnci%2Fdju055) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24777111) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580552) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=US%20incidence%20of%20breast%20cancer%20subtypes%20defined%20by%20joint%20hormone%20receptor%20and%20HER2%20status&journal=J.%20Natl%20Cancer%20Inst.&doi=10.1093%2Fjnci%2Fdju055&publication_year=2014&author=Howlader%2CN) 5. Buonomo, O. C. et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. _PLoS ONE_ **12** , e0184680 (2017). [Article](https://doi.org/10.1371%2Fjournal.pone.0184680) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXotV2gtL8%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28922402) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602519) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20insights%20into%20the%20metastatic%20behavior%20after%20breast%20cancer%20surgery%2C%20according%20to%20well-established%20clinicopathological%20variables%20and%20molecular%20subtypes&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0184680&volume=12&publication_year=2017&author=Buonomo%2COC) 6. Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. _Nat. Rev. Drug Discov._ **22** , 101–126 (2023). [Article](https://doi.org/10.1038%2Fs41573-022-00579-0) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XivVaqt7nJ) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36344672) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Targeting%20HER2-positive%20breast%20cancer%3A%20advances%20and%20future%20directions&journal=Nat.%20Rev.%20Drug%20Discov.&doi=10.1038%2Fs41573-022-00579-0&volume=22&pages=101-126&publication_year=2023&author=Swain%2CSM&author=Shastry%2CM&author=Hamilton%2CE) 7. Grinda, T. et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. _ESMO Open_ **6** , 100114 (2021). [Article](https://doi.org/10.1016%2Fj.esmoop.2021.100114) [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3sbltV2gsg%3D%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33895695) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095121) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Evolution%20of%20overall%20survival%20and%20receipt%20of%20new%20therapies%20by%20subtype%20among%2020%E2%80%89446%20metastatic%20breast%20cancer%20patients%20in%20the%202008-2017%20ESME%20cohort&journal=ESMO%20Open&doi=10.1016%2Fj.esmoop.2021.100114&volume=6&publication_year=2021&author=Grinda%2CT) 8. File, D., Curigliano, G. & Carey, L. A. Escalating and de-escalating therapy for early-stage HER2-positive breast cancer. _Am. Soc. Clin. Oncol. Educ. Book_ (2020). [Article](https://doi.org/10.1200%2Fedbk_100023) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32239987) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Escalating%20and%20de-escalating%20therapy%20for%20early-stage%20HER2-positive%20breast%20cancer&journal=Am.%20Soc.%20Clin.%20Oncol.%20Educ.%20Book&doi=10.1200%2Fedbk_100023&publication_year=2020&author=File%2CD&aut
## Related Clinical Research

- [EHR-driven Analysis of Sequential ADC Orders in Breast Cancer Using Human-Guided Agentic AI](https://medichelpline.com/clinical-feed/medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug.md)
- [Advances in Systemic Treatment of Breast Cancer: Targeted Therapies, ADCs, and Immunotherapy](https://medichelpline.com/clinical-feed/pubmed-42842904.md) (DOI: 10.1056/NEJMra2500695)
- [Immunological effects of antibody–drug conjugates: mechanisms, combos and next‑generation designs](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-exploring-the-immunological-effects-of-antibody-drug-conjugates.md)
- [T-DXd vs Other HER2-targeted Therapies in Later-Line HER2+ Metastatic Breast Cancer: Bayesian NMA](https://medichelpline.com/clinical-feed/pubmed-42809558.md) (DOI: 10.1371/journal.pone.0358540)
- [Trastuzumab + nivolumab with gemcitabine–cisplatin as first-line therapy for HER2-positive unresec](https://medichelpline.com/clinical-feed/nature-3-trastuzumab-plus-nivolumab-with-gemcitabine-and-cisplatin-as-first-line-therapy.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.